| Autor: |
Ali ESER, Funda PEPEDİL TANRIKULU, Aslıhan SEZGİN, Ayşe Tülin TUĞLULAR |
| Jazyk: |
angličtina |
| Rok vydání: |
2019 |
| Předmět: |
|
| Zdroj: |
Bezmiâlem Science, Vol 7, Iss 2, Pp 95-100 (2019) |
| Druh dokumentu: |
article |
| ISSN: |
2148-2373 |
| DOI: |
10.14235/bas.galenos.2018.2003 |
| Popis: |
Objective:Bone marrow involvement (BMI) is a significant component of staging of Hodgkin’s lymphoma (HL). Unilateral bone marrow biopsy (BMB) from dorsal iliac bone is the standard method to determine BMI. Positron emission tomography/computerized tomography (PET/CT) is recommended as a complimentary technique to determine BMI and to evaluate response to treatment. The aim of this study is to determine whether PET/CT can replace BMB to detect BMI in patients with HL.Methods:A total of 159 patients diagnosed as having HL were evaluated retrospectively. One hundred and four patients who met the criteria were included in the study. BMB and PET/CT were performed on all patients during initial staging.Results:Of the 104 patients, 44 (42.3%) and 17 (16.3%) had BMI in PET/CT and BMB respectively. All patients who had BMI in BMB also had involvement in PET/CT. BMB did not detect BMI in 27 patients who had BMI in PET/CT. All 27 patients had partial or complete remission on PET/CT performed at the end of treatment. This finding was regarded as a relative indicator for BMI. PET/CT had a sensitivity and negative predictive value of 100%, specificity of 68.9% and accuracy rate of 74% to determine BMI.Conclusion:We observed that PET/CT and BMB were compatible to determine BMI in patients diagnosed with HL. Unilateral BMB may result false negative especially in cases with focal involvement. Therefore, PET/CT should be considered as a complimentary technique to determine BMI. Staging should be reevaluated in patients who have BMI in PET/CT and a negative BMB treatment should be planned accordingly. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
